30起交易近138亿美元！默沙东达成100亿美元大额并购；艾伯维超19亿美元引进三抗管线 | 一周交易

创鉴汇2025-07-17

据创鉴汇不完全统计，7月7日至7月13日全球生物制药领域共披露30起交易事件，潜在交易总额近138亿美元。上周最重磅的交易当属默沙东（MSD）以100亿美元收购Verona Pharma，这也是2025年迄今创新药领域第二大并购。通过此次收购，默沙东将获得Ohtuvayre（ensifentrine），这是一款PDE3和PDE4双重抑制剂，于2024年6月获美国FDA批准用于治疗成年患者慢性阻塞性...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2552488142?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-17 17:23","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2552488142","market":"us","top_or_hot":-1,"title":"30起交易近138亿美元！默沙东达成100亿美元大额并购；艾伯维超19亿美元引进三抗管线 | 一周交易","media":"创鉴汇","content":"<div>\n<p>据创鉴汇不完全统计，7月7日至7月13日全球生物制药领域共披露30起交易事件，潜在交易总额近138亿美元。上周最重磅的交易当属默沙东（MSD）以100亿美元收购Verona Pharma，这也是2025年迄今创新药领域第二大并购。通过此次收购，默沙东将获得Ohtuvayre（ensifentrine），这是一款PDE3和PDE4双重抑制剂，于2024年6月获美国FDA批准用于治疗成年患者慢性阻塞性...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717173302a6af7815&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>30起交易近138亿美元！默沙东达成100亿美元大额并购；艾伯维超19亿美元引进三抗管线 | 一周交易</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n30起交易近138亿美元！默沙东达成100亿美元大额并购；艾伯维超19亿美元引进三抗管线 | 一周交易\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-17 17:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717173302a6af7815&s=b><strong>创鉴汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>据创鉴汇不完全统计，7月7日至7月13日全球生物制药领域共披露30起交易事件，潜在交易总额近138亿美元。上周最重磅的交易当属默沙东（MSD）以100亿美元收购Verona Pharma，这也是2025年迄今创新药领域第二大并购。通过此次收购，默沙东将获得Ohtuvayre（ensifentrine），这是一款PDE3和PDE4双重抑制剂，于2024年6月获美国FDA批准用于治疗成年患者慢性阻塞性...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717173302a6af7815&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1162221912.USD","symbol_name":"FRANKLIN INCOME \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717173302a6af7815&s=b","article_id":"2552488142","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717173302a6af7815&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552488142","pubTimestamp":1752744181,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"据创鉴汇不完全统计，7月7日至7月13日全球生物制药领域共披露30起交易事件，潜在交易总额近138亿美元。上周最重磅的交易当属默沙东以100亿美元收购Verona Pharma，这也是2025年迄今创新药领域第二大并购。本次交易不仅巩固了默沙东在心肺疾病领域的产品管线，还进一步强化了其在慢性疾病治疗市场的竞争优势。上周CGT领域交易增多，涉及4起基因疗法技术合作，1起CAR-T领域并购及1起干细胞移植治疗的合作研发。上周中国公司达成多起跨国交易。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4007":"制药","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","02616":"基石药业-B","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","AZN":"阿斯利康","LU0058720904.USD":"联博国际健康护理基金A","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","MRK":"默沙东","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0238689110.USD":"贝莱德环球动力股票基金","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC"},"translate_title":"Nearly $13.8 billion in 30 transactions! Merck reached a large merger of US $10 billion; AbbVie introduces tertiary antibody pipeline for over US $1.9 billion | One-week transaction","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"MRK":1,"02616":0.9},"content_text":"据创鉴汇不完全统计，7月7日至7月13日全球生物制药领域共披露30起交易事件，潜在交易总额近138亿美元。上周最重磅的交易当属默沙东（MSD）以100亿美元收购Verona Pharma，这也是2025年迄今创新药领域第二大并购。通过此次收购，默沙东将获得Ohtuvayre（ensifentrine），这是一款PDE3和PDE4双重抑制剂，于2024年6月获美国FDA批准用于治疗成年患者慢性阻塞性肺病（COPD）。本次交易不仅巩固了默沙东在心肺疾病领域的产品管线，还进一步强化了其在慢性疾病治疗市场的竞争优势。继6月30日超20亿美元并购之后，艾伯维（Abbvie）又有新动作，以7亿美元首付款，潜在交易总额19.25亿美元获得Ichnos Glenmark Innovation的三特异性抗体ISB-2001的独家许可协议。该药物靶向骨髓瘤细胞上的BCMA和CD38，以及T细胞上的CD3，有望克服耐药性并改善难治性癌症预后，目前正在多发性骨髓瘤患者中进行1期临床试验。上周CGT领域交易增多，涉及4起基因疗法技术合作，1起CAR-T领域并购及1起干细胞移植治疗的合作研发。其中，JCR Pharmaceuticals将其专有JUST-AAV衣壳技术以潜在总额8.25亿美元授权给阿斯利康罕见病子公司Alexion，后者可将该技术应用于多达5个基因药物项目。这也是双方第三次合作。在CAR-T领域，CARGO Therapeutics被Concentra以2.175亿美元并购，进一步强化布局。此外，其他基因疗法合作还包括Amarna与NorthX携手推进1型糖尿病基因疗法Nimvec AM510的临床开发等。这些交易显示出CGT领域在技术创新上的活跃度和潜力。与此同时，AI赋能药物研发同样受到关注，上周也促成了多项重要合作。例如，中外制药（Chugai）与新加坡Gero合作利用AI挖掘与年龄相关疾病的新靶点，并开发新型抗体候选药物。Gero将获得约2.5亿美元款项。上周中国公司达成多起跨国交易。基石药业将舒格利单抗西欧和英国的独家商业化权利，以潜在总额1.925亿美元授权给Istituto Gentili。维泰瑞隆与诺华达成脑部递送模组平台的战略协议。该平台是一种差异化的血脑屏障穿透技术，旨在提高多种形式药物的脑部递送效率。读者们请星标⭐创鉴汇，第一时间收到推送","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552488142","isCrawlerRequest":true}